Diagnostic performance of fecal eosinophil-derived neurotoxin and lipocalin-2 in pediatric inflammatory bowel disease - Takeaways - MDSpire

Evaluating the Diagnostic Efficacy of Fecal Eosinophil-Derived Neurotoxin and Lipocalin-2 in Children with Inflammatory Bowel Disease

  • By

  • Ragaey Ahmad Eid

  • Nada Atteya Fakhry

  • Doaa Mabrouk Ahmed

  • Mahmoud Hodeib

  • July 17, 2026

Share

  • 1

    Inflammatory bowel diseases (IBD) in children include ulcerative colitis, Crohn’s disease, and IBD-unclassified, with rising incidence rates.

  • 2

    The diagnosis of IBD involves clinical presentation, endoscopic evaluation, and histological assessment of intestinal mucosa.

  • 3

    Fecal eosinophil-derived neurotoxin (fEDN) and lipocalin-2 (LCN-2) are being evaluated as non-invasive biomarkers for pediatric IBD.

  • 4

    The study included 90 participants divided into three groups: IBD patients, healthy children, and children with acute diarrhea.

  • 5

    Inclusion criteria for the study were children under 18 years diagnosed with IBD who provided informed consent.

Original Source(s)

Diagnostic performance of fecal eosinophil-derived neurotoxin and lipocalin-2 in pediatric inflammatory bowel disease

  • by Ragaey Ahmad Eid, Nada Atteya Fakhry, Doaa Mabrouk Ahmed, Mahmoud Hodeib

  • July 17, 2026

Related Content

Uptake and Use of Biologic Therapies in Paediatric Immune-Mediated Inflammatory Diseases: An Australian Population-Based Study

Spatial genetic mapping links shared inflammatory bowel disease liability to adult immune–epithelial lesion contexts

Selective COX-2 inhibitors for short-term musculoskeletal pain in inflammatory bowel disease in remission: a narrative review